scPharmaceuticals, Inc. $SCPH Shares Acquired by Apis Capital Advisors LLC

Key Points

• Apis Capital Advisors LLC increased its stake in scPharmaceuticals by 28.2% in Q1, holding approximately 1.00% of the company, valued at $1.33 million.
• Several analysts have recently downgraded scPharmaceuticals, with a consensus rating of "Hold" and a target price of $12.00.
• scPharmaceuticals reported a quarterly EPS of ($0.34), missing estimates, although it exceeded revenue expectations with $16.04 million for the period.

Apis Capital Advisors LLC raised its stake in shares of scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) by 28.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 504,947 shares of the company's stock after purchasing an additional 110,947 shares during the period. Apis Capital Advisors LLC owned 1.00% of scPharmaceuticals worth $1,328,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Chicago Partners Investment Group LLC purchased a new stake in scPharmaceuticals in the 1st quarter worth about $31,000. Assenagon Asset Management S.A. purchased a new stake in shares of scPharmaceuticals in the first quarter valued at approximately $33,000. Legato Capital Management LLC boosted its holdings in shares of scPharmaceuticals by 48.1% in the first quarter. Legato Capital Management LLC now owns 15,275 shares of the company's stock valued at $40,000 after purchasing an additional 4,961 shares during the period. Perkins Capital Management Inc. boosted its holdings in shares of scPharmaceuticals by 41.0% in the first quarter. Perkins Capital Management Inc. now owns 17,200 shares of the company's stock valued at $45,000 after purchasing an additional 5,000 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in shares of scPharmaceuticals in the fourth quarter valued at approximately $48,000. Institutional investors own 89.52% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on SCPH. Wall Street Zen raised shares of scPharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Craig Hallum downgraded shares of scPharmaceuticals from a "buy" rating to a "hold" rating and set a $6.00 target price for the company. in a research note on Monday, August 25th. Maxim Group lowered shares of scPharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, August 25th. Finally, HC Wainwright lowered shares of scPharmaceuticals from a "strong-buy" rating to a "hold" rating and set a $5.35 price target on the stock. in a report on Friday, August 29th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $7.78.

scPharmaceuticals Price Performance

Shares of SCPH stock traded down $0.02 during mid-day trading on Friday, hitting $5.57. 402,035 shares of the stock were exchanged, compared to its average volume of 599,174. The company has a market cap of $296.61 million, a PE ratio of -3.07 and a beta of 0.35. scPharmaceuticals, Inc. has a 52-week low of $1.94 and a 52-week high of $6.28. The firm has a fifty day moving average of $4.87 and a 200 day moving average of $3.70. The company has a quick ratio of 3.14, a current ratio of 3.85 and a debt-to-equity ratio of 3.86.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.04). scPharmaceuticals had a negative net margin of 183.55% and a negative return on equity of 1,647.86%. The company had revenue of $16.04 million during the quarter, compared to analysts' expectations of $15.41 million. Research analysts anticipate that scPharmaceuticals, Inc. will post -1.53 earnings per share for the current year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.